Diethylcarbamazine
Diethylcarbamazine[edit]
Diethylcarbamazine (DEC) is a medication used in the treatment of certain parasitic diseases, primarily lymphatic filariasis, tropical pulmonary eosinophilia, and loiasis. It is an anti-parasitic drug that works by killing the microfilariae and adult worms of susceptible species.
Mechanism of Action[edit]
Diethylcarbamazine works by altering the surface structure of the microfilariae, making them more susceptible to destruction by the host's immune system. It also affects the muscular activity of the parasites, leading to their immobilization and eventual death. The exact mechanism of action is not fully understood, but it is known to involve interference with arachidonic acid metabolism in the parasites.
Uses[edit]
Diethylcarbamazine is primarily used to treat:
- Lymphatic filariasis: A disease caused by infection with the filarial worms Wuchereria bancrofti, Brugia malayi, and Brugia timori.
- Loiasis: Also known as African eye worm, caused by the filarial worm Loa loa.
- Tropical pulmonary eosinophilia: A syndrome associated with filarial infections, characterized by cough, wheezing, and eosinophilia.
Administration[edit]
Diethylcarbamazine is administered orally, usually in the form of tablets. The dosage and duration of treatment depend on the specific infection being treated and the patient's response to the medication. It is important to follow the prescribed regimen to ensure the effectiveness of the treatment.
Side Effects[edit]
Common side effects of diethylcarbamazine include:
- Headache
- Dizziness
- Nausea
- Vomiting
- Loss of appetite
In some cases, patients may experience more severe reactions due to the rapid killing of microfilariae, such as fever, rash, and muscle pain. These reactions are generally self-limiting and can be managed with supportive care.
Precautions[edit]
Before starting treatment with diethylcarbamazine, it is important to assess the patient's overall health and any potential contraindications. Patients with a high burden of microfilariae may require hospitalization during the initial phase of treatment to manage any severe reactions.
